Cancer

October 21, 2024

Since the first ADC drug Mylotarg (gemtuzumab ozogamicin) was approved by the FDA in 2000, a total of 15 ADC drugs have been approved for marketing worldwide to treat hematological malignancies and solid tumors. In addition, more than 400 ADC drugs are in different stages of development. Of the 15 approved ADC drugs, 13 are […]

August 24, 2024

Metabolic changes are a hallmark of cancer, supporting the rapid proliferation and survival of cancer under various stress conditions. Some metabolic activities have important detoxification functions, which prevent excessive accumulation of toxic metabolic intermediates. There is a "kitchen sink" model in cancer cells, where detoxification enzymes are needed only when the content of toxic metabolites in […]

July 26, 2024

Early detection of cancer and prediction of treatment response continue to face significant challenges. Recently, liquid biopsies have been further extended to analyze Glycoproteins. Glycoproteins are products of post-translational modifications of proteins and play a key role in normal and pathological processes, including cancer. Glycoproteomic analysis has emerged as a promising tool for the discovery […]